-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

Benzinga·08/14/2026 16:00:13
Listen to the news
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.